https://pbs.twimg.com/media/EZqtgbGUEAAaY2t.jpg
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0

Links:

E-CONGRESS https://eular.conference2web.com/#!resources/secukinumab-150-mg-significantly-i…
Dr Philip Robinson
philipcrobinson
05-06-2020
×